Long Non-Coding RNAs (lncRNAs) in Heart Failure: A Comprehensive Review

Abstract

Heart failure (HF) is a widespread cardiovascular condition that poses significant risks to a wide spectrum of age groups and leads to terminal illness. Although our understanding of the underlying mechanisms of HF has improved, the available treatments still remain inadequate. Recently, long non-coding RNAs (lncRNAs) have emerged as crucial players in cardiac function, showing possibilities as potential targets for HF therapy. These versatile molecules interact with chromatin, proteins, RNA, and DNA, influencing gene regulation. Notable lncRNAs like Fendrr, Trpm3, and Scarb2 have demonstrated therapeutic potential in HF cases. Additionally, utilizing lncRNAs to forecast survival rates in HF patients and distinguish various cardiac remodeling conditions holds great promise, offering significant benefits in managing cardiovascular disease and addressing its far-reaching societal and economic impacts. This underscores the pivotal role of lncRNAs in the context of HF research and treatment.

Non-coding RNAs: targets for Chinese herbal medicine in treating myocardial fibrosis

“…Compared with miRNA, the length of lncRNA is usually longer, generally more than 200 nt, which has the similar structure with mRNA ( Jha et al, 2023 ). Firstly, ceRNA mechanism is one of the important ways for lncRNA to regulate genes ( Huang, 2018 ).…”